7-Tesla MRI in Epilepsy

7-Tesla (7T) MRI is an ultra-high-field magnetic resonance imaging technique that can reveal subtle structural abnormalities not seen on conventional 1.5T or 3T scans. In epilepsy, its main value is in selected people with drug-resistant focal epilepsy, especially when standard MRI is reported as normal or equivocal.

Why field strength matters

A stronger magnetic field increases signal-to-noise ratio and can support thinner slices, higher spatial resolution and greater contrast between tissues.

This can make subtle cortical abnormalities easier to see, particularly focal cortical dysplasia, small vascular lesions and abnormalities of the hippocampus.

Who is most likely to benefit?

7T MRI is not a replacement for a well-performed dedicated epilepsy MRI at 3T.

Its greatest clinical role is usually in complex presurgical evaluation when high-quality 3T imaging has not identified a lesion that fits the seizure data.

MRI-negative epilepsy

“MRI-negative” means no causal lesion has been identified on available imaging. It does not mean the brain is structurally normal.

Some lesions are simply below the detection threshold of standard imaging or become visible only after specialist re-review, post-processing or higher-field imaging.

Focal cortical dysplasia

Focal cortical dysplasia can be extremely subtle. Abnormal cortical thickness, blurring of the grey–white junction and small transmantle abnormalities may be more conspicuous at 7T.

This matters because identifying a lesion can change surgical planning and the placement of intracranial electrodes.

Hippocampal abnormalities

7T can provide very high-resolution views of hippocampal internal architecture.

This may help characterise abnormalities in mesial temporal lobe epilepsy when conventional imaging is inconclusive.

Vascular lesions

Cavernomas, developmental venous abnormalities and other small vascular lesions can be better characterised with susceptibility-sensitive 7T sequences.

What the evidence shows

A systematic review and meta-analysis found higher detection of morphological abnormalities at 7T than at lower field strengths in focal epilepsy studies.

A 2025 review also concluded that 7T may reveal lesions occult on conventional MRI, particularly focal cortical dysplasia and other cortical malformations.

Why 7T is not automatically “better”

Higher field strength also increases artefacts, field inhomogeneity and technical complexity.

Some areas of the brain can actually be harder to image without optimised sequences.

Safety and implants

Not every device approved for 1.5T or 3T scanning is approved for 7T.

People with implanted stimulators, clips or other metallic devices require specific safety assessment.

Children

Paediatric 7T imaging is technically feasible in specialist centres but may be limited by motion, scanning time, implant restrictions and the need to avoid or minimise sedation.

7T and MRI post-processing

Ultra-high-field MRI can be combined with morphometric or other computational post-processing.

These approaches are complementary: stronger imaging may reveal more anatomy, while post-processing can highlight patterns that remain visually subtle.

Does finding a lesion prove it causes seizures?

No.

A 7T abnormality must still be interpreted alongside seizure semiology, scalp EEG, PET/SPECT/MEG where relevant, neuropsychology and sometimes intracranial EEG.

Incidental findings

Higher-resolution scanning can also reveal abnormalities unrelated to epilepsy.

This creates a need for expert neuroradiological interpretation rather than assuming every visible difference is epileptogenic.

Worldwide access

7T scanners remain concentrated in tertiary academic centres and wealthier health systems.

Cost, specialist staffing, regulatory approval and implant compatibility all limit worldwide access.

The central point

7T MRI is a specialist problem-solving tool, not a routine replacement for 3T epilepsy MRI. Its greatest value is in difficult focal epilepsy where a hidden structural lesion could change surgical management.

Sources

Evidence checked: September 2026.